REGENXBIO Gains $100M AbbVie Milestone as NAAVIGATE Pivotal Trial Doses First Patient

A $100 million milestone payment to REGENXBIO from AbbVie signals that surabgene lomparvovec (sura-vec; ABBV-RGX-314) has cleared the threshold into pivotal-stage development, a transition that carries direct implications for ATMP manufacturers managing AAV vector scale-up under GMP conditions. The first patient has been dosed in the phase 2b/3 NAAVIGATE trial, evaluating a one-time suprachoroidal gene therapy for nonproliferative diabetic retinopathy (NPDR) without center-involved macular edema.

Sura-vec uses the NAV AAV8 vector to deliver a gene encoding an anti-VEGF antibody fragment to retinal tissue, enabling sustained endogenous VEGF inhibition following a single in-office administration. Delivery is via the suprachoroidal route, placing the vector between the choroid and sclera without vitreous entry, a method that introduces distinct biodistribution considerations relative to intravitreal or subretinal approaches and bears on fill-finish and device compatibility requirements at the manufacturing level.

NAAVIGATE is a multicenter, randomized, masked, sham-controlled study. Patients receive sura-vec at 1.0×10¹² genome copies per eye, the dose level evaluated as dose level 3 in the earlier phase 2 ALTITUDE trial, alongside short-course topical prophylactic steroids. The primary endpoint is a greater than 2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at one year. The phase 2b portion, operationalized by REGENXBIO, targets approximately 135 participants across U.S. sites.

The clinical rationale rests on a documented gap in the current standard of care. Real-world anti-VEGF injection frequencies for diabetic macular edema range from 2.2 to 4.4 injections per year, well below the dosing intensity that produces optimal outcomes in controlled trials. One-fifth of patients cite injection fear as a barrier to treatment. A durable single-administration approach, if validated at pivotal scale, would directly address that adherence gap across a population of nearly 10 million Americans affected by DR.

Two-year data from the ALTITUDE phase 2 trial, presented earlier in 2026, showed sura-vec at dose level 3 was well tolerated with no intraocular inflammation observed in 15 patients and demonstrated improvement in diabetic retinopathy severity scores alongside reduced treatment burden, the efficacy and safety profile that supported progression to NAAVIGATE.

For ATMP manufacturers and QA leads supporting pivotal CGT programs, the NAAVIGATE enrollment timeline and the phase 2b/3 structure set a near-term checkpoint: process validation packages and batch release standards aligned with 21 CFR Part 211 and ICH Q10 quality system expectations will need to be in place well ahead of any BLA submission horizon tied to the one-year primary endpoint readout.

Source: CGTlive® via REGENXBIO press release, July 7, 2026.